These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 19034451)

  • 1. Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies.
    Mita M; Mita A; Sarantopoulos J; Takimoto CH; Rowinsky EK; Romero O; Angiuli P; Allievi C; Eisenfeld A; Verschraegen CF
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):287-95. PubMed ID: 19034451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules.
    Boddy AV; Plummer ER; Todd R; Sludden J; Griffin M; Robson L; Cassidy J; Bissett D; Bernareggi A; Verrill MW; Calvert AH
    Clin Cancer Res; 2005 Nov; 11(21):7834-40. PubMed ID: 16278406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors.
    Verschraegen CF; Skubitz K; Daud A; Kudelka AP; Rabinowitz I; Allievi C; Eisenfeld A; Singer JW; Oldham FB
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):903-10. PubMed ID: 18682950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.
    Sabbatini P; Sill MW; O'Malley D; Adler L; Secord AA;
    Gynecol Oncol; 2008 Dec; 111(3):455-60. PubMed ID: 18829087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel poliglumex (PPX-Xyotax) and concurrent radiation for esophageal and gastric cancer: a phase I study.
    Dipetrillo T; Milas L; Evans D; Akerman P; Ng T; Miner T; Cruff D; Chauhan B; Iannitti D; Harrington D; Safran H
    Am J Clin Oncol; 2006 Aug; 29(4):376-9. PubMed ID: 16891865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors.
    Nemunaitis J; Cunningham C; Senzer N; Gray M; Oldham F; Pippen J; Mennel R; Eisenfeld A
    Cancer Invest; 2005; 23(8):671-6. PubMed ID: 16377585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies.
    Nyman DW; Campbell KJ; Hersh E; Long K; Richardson K; Trieu V; Desai N; Hawkins MJ; Von Hoff DD
    J Clin Oncol; 2005 Nov; 23(31):7785-93. PubMed ID: 16258082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies.
    Homsi J; Simon GR; Garrett CR; Springett G; De Conti R; Chiappori AA; Munster PN; Burton MK; Stromatt S; Allievi C; Angiuli P; Eisenfeld A; Sullivan DM; Daud AI
    Clin Cancer Res; 2007 Oct; 13(19):5855-61. PubMed ID: 17908979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies.
    Advani R; Fisher GA; Lum BL; Jambalos C; Cho CD; Cohen M; Gollerkeri A; Sikic BI
    Clin Cancer Res; 2003 Nov; 9(14):5187-94. PubMed ID: 14613998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies.
    Fracasso PM; Picus J; Wildi JD; Goodner SA; Creekmore AN; Gao F; Govindan R; Ellis MJ; Tan BR; Linette GP; Fu CJ; Pentikis HS; Zumbrun SC; Egorin MJ; Bellet RE
    Cancer Chemother Pharmacol; 2009 Feb; 63(3):451-8. PubMed ID: 18414864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy.
    Brenner B; Ilson DH; Minsky BD; Bains MS; Tong W; Gonen M; Kelsen DP
    J Clin Oncol; 2004 Jan; 22(1):45-52. PubMed ID: 14701767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial.
    Loibl S; Murmann C; Schwedler K; Warm M; Müller L; Heinrich G; Nekljudova V; von Minckwitz G
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):953-8. PubMed ID: 18716777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies.
    Kim TY; Kim DW; Chung JY; Shin SG; Kim SC; Heo DS; Kim NK; Bang YJ
    Clin Cancer Res; 2004 Jun; 10(11):3708-16. PubMed ID: 15173077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A tolerability study of A cremophor-free albumin bound nanoparticle paclitaxel intravenously administered in patients with advanced solid tumor].
    Teng XY; Guan ZZ; Yao ZW; Liu DG; Zhou NN; Luo HY; Hawkins M; Soon-Shiong P
    Ai Zheng; 2004 Nov; 23(11 Suppl):1431-6. PubMed ID: 15566651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel.
    Mita AC; Olszanski AJ; Walovitch RC; Perez RP; MacKay K; Tuck DP; Simmons C; Hammond S; Mita MM; Beeram M; Stone AJ; Rowinsky EK; Lewis LD
    Clin Cancer Res; 2007 Jun; 13(11):3293-301. PubMed ID: 17545535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase i study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer.
    Matsubara J; Shimada Y; Takashima A; Takahari D; Hirashima Y; Okita NT; Nakajima TE; Kato K; Hamaguchi T; Yamada Y; Shirao K
    Jpn J Clin Oncol; 2008 Aug; 38(8):540-6. PubMed ID: 18628316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors.
    Lockhart AC; Bukowski R; Rothenberg ML; Wang KK; Cooper W; Grover J; Appleman L; Mayer PR; Shapiro M; Zhu AX
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):203-9. PubMed ID: 17091249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.
    Rizvi NA; Riely GJ; Azzoli CG; Miller VA; Ng KK; Fiore J; Chia G; Brower M; Heelan R; Hawkins MJ; Kris MG
    J Clin Oncol; 2008 Feb; 26(4):639-43. PubMed ID: 18235124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-time pharmacokinetics guiding clinical decisions; phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours.
    Soepenberg O; Sparreboom A; de Jonge MJ; Planting AS; de Heus G; Loos WJ; Hartman CM; Bowden C; Verweij J
    Eur J Cancer; 2004 Mar; 40(5):681-8. PubMed ID: 15010068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel.
    Fetterly GJ; Grasela TH; Sherman JW; Dul JL; Grahn A; Lecomte D; Fiedler-Kelly J; Damjanov N; Fishman M; Kane MP; Rubin EH; Tan AR
    Clin Cancer Res; 2008 Sep; 14(18):5856-63. PubMed ID: 18794097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.